{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T13:30:24Z","timestamp":1769347824638,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Novel therapeutic strategies have shown some promise in treating spinal muscular atrophy (SMA). However, the outcomes and acceptance of these new strategies are yet to be explored. We aimed to investigate physicians' opinions and perceptions toward management strategies of SMA across Saudi Arabia. This is a cross-sectional survey using a self-administered, structured questionnaire sent to physicians who care for SMA patients during the Saudi Pediatric Neurology Society annual conference. A total of 72 clinicians of different neurological subspecialties were included. 48.6% prescribed nusinersen to their patients, with 39% of them having patients started on nusinersen. Though, 8.3% prescribed onasemnogene abeparvovec for 1\u20133 patients, while none of their patients started on the treatment. 64.3% stated that the only treatment available for SMA in their settings is supportive care. Around 69.4% described having a moderate to high knowledge on SMA gene therapy, and 79.2% would recommend it. 48.6% confirmed they would prescribe gene therapy at the age of 6 months, and 78.3% would prescribe it for type-I SMA. Pediatric neurologists are receptive to novel and innovative therapies for SMA in Saudi Arabia. However, the high treatment acquisition cost, strict regulations, logistical issues, and budget constraints delay their adoption and implementation.<\/jats:p>","DOI":"10.3389\/fped.2021.684134","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T04:23:00Z","timestamp":1622434980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia"],"prefix":"10.3389","volume":"9","author":[{"given":"Fahad A.","family":"Bashiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad-Hani","family":"Temsah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Hundallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Alsohime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazed","family":"AlRuthia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/14728214.2015.1041375","article-title":"Moving towards treatments for spinal muscular atrophy: hopes and limits","volume":"20","author":"Wirth","year":"2015","journal-title":"Expert Opin Emerg Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","article-title":"Spinal muscular atrophy\u2013recent therapeutic advances for an old challenge","volume":"11","author":"Faravelli","year":"2015","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"B4","unstructured":"Spinal muscular atrophy PriorTW LeachME FinangerE AdamMP ArdingerHH PagonRA WallaceSE BeanLJH MirzaaG Seattle, WAUniversity of Washington2000"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000110905","article-title":"Epidemiology of spinal muscular atrophies in a sample of the Italian population","volume":"11","author":"Mostacciuolo","year":"1992","journal-title":"Neuroepidemiology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy","volume":"15","author":"Pearn","year":"1978","journal-title":"J Med Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1756285618754501","DOI":"10.1177\/1756285618754501","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","author":"Parente","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nature Rev Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1016-1002","article-title":"Big win possible for ionis\/biogen antisense drug in muscular atrophy","volume":"34","author":"Garber","year":"2016","journal-title":"Nat Biotechnol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fnmol.2016.00076","article-title":"Neuroprotective effect of non-viral gene therapy treatment based on tetanus toxin C-fragment in a severe mouse model of spinal muscular atrophy","volume":"9","author":"Oliv\u00e1n","year":"2016","journal-title":"Front Mol Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve."},{"key":"B17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B19","unstructured":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tips.2019.10.009","article-title":"Oligonucleotides to the (gene) rescue: FDA approvals 2017\u20132019","volume":"41","author":"R\u00fcger","year":"2020","journal-title":"Trends Pharmacol Sci."},{"key":"B21","unstructured":"FDA Approves Innovative Gene Therapy to Treat Pediatric Patients With Spinal Muscular Atrophy a Rare Disease and Leading Genetic Cause of Infant Mortality"},{"key":"B22","unstructured":"Zolgensma"},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1021\/acs.jmedchem.6b00459","article-title":"Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy","volume":"59","author":"Ratni","year":"2016","journal-title":"J Med Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/gt.2017.79","article-title":"Market access of spinraza (nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations","volume":"24","author":"Simoens","year":"2017","journal-title":"Gene Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.17712\/nsj.2019.1.20180321","article-title":"Effect of new modalities of treatment on physicians management plan for patients with spinal muscular atrophy","volume":"24","author":"Bashiri","year":"2019","journal-title":"Neurosciences."},{"key":"B28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ppul.21617","article-title":"International survey of physician recommendation for tracheostomy for spinal muscular atrophy type I","volume":"47","author":"Benson","year":"2012","journal-title":"Pediatr Pulmonol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1177\/0883073810381924","article-title":"Consensus statement on standard of care for congenital muscular dystrophies","volume":"25","author":"Wang","year":"2010","journal-title":"J Child Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/WCO.0000000000000368","article-title":"Advances in modeling and treating spinal muscular atrophy","volume":"29","author":"Van","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.1828","article-title":"Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): Phase 3 US study (STR1VE) update 1828","author":"Day","year":"2020","journal-title":"Neurol."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S25.003","article-title":"FIREFISH part 1: 1-year results on motor function in babies with type 1 SMA (S25","author":"Baranello","year":"2019","journal-title":"Neurol."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.1260","article-title":"SUNFISH part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) 1260","author":"Mercuri","year":"2020","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De","year":"2019","journal-title":"Neuromusc Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J Mark Access Health Policy."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.18553\/jmcp.2019.25.12.1306","article-title":"Spinal Muscular atrophy therapies: ICER grounds the price to value conversation in facts","volume":"25","author":"Starner","year":"2019","journal-title":"J Manag Care Spec Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/s-0037-1598105","article-title":"Pediatric neurology workforce in Saudi Arabia","volume":"15","author":"Al-Nahdi","year":"2017","journal-title":"J Pediatr Neurol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.684134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T20:56:49Z","timestamp":1725137809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.684134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":41,"alternative-id":["10.3389\/fped.2021.684134"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.684134","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"684134"}}